An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation
<a href="https://pixabay.com/users/Versatilevick_media/">Versatilevick_media</a> / Pixabay

An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation

According to a story from firstworldpharma.com, the biopharmaceutical company Acceleron Pharma, Inc., recently announced that the company's experimental product candidate sotatercept has earned Orphan Drug designation from the US Food…

Continue Reading
Close Menu